Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41582-018-0112-x.

Title:
Myelin oligodendrocyte glycoprotein antibodies in neurological disease | Nature Reviews Neurology
Description:
Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their association with multiple sclerosis (MS) was not specific. Use of cell-based assays with native MOG as the substrate enabled identification of a group of MOG-Ab-positive patients with demyelinating phenotypes. Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM). Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes (optic neuritis, myelitis and brainstem encephalitis), but rarely in MS. This shift in our understanding of the diagnostic assays has re-invigorated the examination of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS. The clinical phenotypes, disease courses and responses to treatment that are associated with MOG-Abs are currently being defined. MOG-Ab-associated disease is different to AQP4-Ab-positive NMOSD and MS. This Review provides an overview of the current knowledge of MOG, the metrics of MOG-Ab assays and the clinical associations identified. We collate the data on antibody pathogenicity and the mechanisms that are thought to underlie this. We also highlight differences between MOG-Ab-associated disease, NMOSD and MS, and describe our current understanding on how best to treat MOG-Ab-associated disease. In this Review, Reindl and Waters provide an overview of what we currently know about anti-myelin oligodendrocyte glycoprotein antibodies and their association with demyelinating diseases, including the value of detection assays and evidence for antibody pathogenicity and its mechanism.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $42,042 to $115,616.

Keywords {🔍}

pubmed, google, scholar, cas, glycoprotein, central, antibodies, neurol, oligodendrocyte, myelin, mog, multiple, sclerosis, patients, disease, demyelinating, clinical, mogabs, disorders, neuromyelitis, optica, nature, study, neuroinflamm, spectrum, optic, neuritis, antibody, neurology, children, encephalomyelitis, neuroimmunol, mult, scler, article, encephalitis, nmosd, cns, diseases, brain, aquaporin, antimog, studies, autoantibodies, antimyelin, syndromes, autoimmune, inflammatory, access, mogigg,

Topics {✒️}

anti-n-methyl-d-aspartate receptor encephalitis nature portfolio journals nature portfolio permissions reprints privacy policy 3ʹ-cyclic nucleotide 3ʹ-phosphodiesterase editing advertising english-language social media author information authors mog-igg-positive multifocal myelitis nature+ nature 478 nature myelin-reactive antibodies initiate autoantibody-mediated cns conditions central nervous system received research funding india mhc haplotype-dependent regulation development anti-myelin oligodendrocyte glycoprotein china life sci bilaterale myelin-oligodendrozyten-glykoprotein guthy-jackson charitable foundation anti-mbp antibody subclasses myelin/oligodendrocyte glycoprotein-deficient author correspondence �pattern ii multiple sclerosis myelin-oligodendrocyte glycoprotein antibodies double-transgenic mouse model myelin oligodendrocyte glycoprotein-specific enzyme-linked immunosorbent assay childhood-acquired demyelinating syndromes research grants live cell-based assay anti-mog antibodies plead neuromyelitis optica mog-igg relapsing-remitting multiple sclerosis mog-igg-positive case population-based prospective study permissions myelin oligodendrocyte glycoprotein myelin/oligodendrocyte glycoprotein myelin-oligodendrocyte glycoprotein myelin-oligodendrocyte-glycoprotein aqp4-ab-positive nmosd china springerlink instant access

Questions {❓}

  • Optikusneuritis – Patient sieht nichts, Arzt sieht nichts?
  • Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?
  • What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Myelin oligodendrocyte glycoprotein antibodies in neurological disease
         description:Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their association with multiple sclerosis (MS) was not specific. Use of cell-based assays with native MOG as the substrate enabled identification of a group of MOG-Ab-positive patients with demyelinating phenotypes. Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM). Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes (optic neuritis, myelitis and brainstem encephalitis), but rarely in MS. This shift in our understanding of the diagnostic assays has re-invigorated the examination of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS. The clinical phenotypes, disease courses and responses to treatment that are associated with MOG-Abs are currently being defined. MOG-Ab-associated disease is different to AQP4-Ab-positive NMOSD and MS. This Review provides an overview of the current knowledge of MOG, the metrics of MOG-Ab assays and the clinical associations identified. We collate the data on antibody pathogenicity and the mechanisms that are thought to underlie this. We also highlight differences between MOG-Ab-associated disease, NMOSD and MS, and describe our current understanding on how best to treat MOG-Ab-associated disease. In this Review, Reindl and Waters provide an overview of what we currently know about anti-myelin oligodendrocyte glycoprotein antibodies and their association with demyelinating diseases, including the value of detection assays and evidence for antibody pathogenicity and its mechanism.
         datePublished:2018-12-17T00:00:00Z
         dateModified:2018-12-17T00:00:00Z
         pageStart:89
         pageEnd:102
         sameAs:https://doi.org/10.1038/s41582-018-0112-x
         keywords:
            Demyelinating diseases
            Immunological disorders
            Neuroimmunology
            Medicine/Public Health
            general
            Neurology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig3_HTML.png
         isPartOf:
            name:Nature Reviews Neurology
            issn:
               1759-4766
               1759-4758
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Markus Reindl
               url:http://orcid.org/0000-0003-2817-1402
               affiliation:
                     name:Medical University of Innsbruck
                     address:
                        name:Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Patrick Waters
               affiliation:
                     name:University of Oxford
                     address:
                        name:Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Myelin oligodendrocyte glycoprotein antibodies in neurological disease
      description:Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their association with multiple sclerosis (MS) was not specific. Use of cell-based assays with native MOG as the substrate enabled identification of a group of MOG-Ab-positive patients with demyelinating phenotypes. Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM). Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes (optic neuritis, myelitis and brainstem encephalitis), but rarely in MS. This shift in our understanding of the diagnostic assays has re-invigorated the examination of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS. The clinical phenotypes, disease courses and responses to treatment that are associated with MOG-Abs are currently being defined. MOG-Ab-associated disease is different to AQP4-Ab-positive NMOSD and MS. This Review provides an overview of the current knowledge of MOG, the metrics of MOG-Ab assays and the clinical associations identified. We collate the data on antibody pathogenicity and the mechanisms that are thought to underlie this. We also highlight differences between MOG-Ab-associated disease, NMOSD and MS, and describe our current understanding on how best to treat MOG-Ab-associated disease. In this Review, Reindl and Waters provide an overview of what we currently know about anti-myelin oligodendrocyte glycoprotein antibodies and their association with demyelinating diseases, including the value of detection assays and evidence for antibody pathogenicity and its mechanism.
      datePublished:2018-12-17T00:00:00Z
      dateModified:2018-12-17T00:00:00Z
      pageStart:89
      pageEnd:102
      sameAs:https://doi.org/10.1038/s41582-018-0112-x
      keywords:
         Demyelinating diseases
         Immunological disorders
         Neuroimmunology
         Medicine/Public Health
         general
         Neurology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41582-018-0112-x/MediaObjects/41582_2018_112_Fig3_HTML.png
      isPartOf:
         name:Nature Reviews Neurology
         issn:
            1759-4766
            1759-4758
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Markus Reindl
            url:http://orcid.org/0000-0003-2817-1402
            affiliation:
                  name:Medical University of Innsbruck
                  address:
                     name:Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Patrick Waters
            affiliation:
                  name:University of Oxford
                  address:
                     name:Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Neurology
      issn:
         1759-4766
         1759-4758
      volumeNumber:15
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Medical University of Innsbruck
      address:
         name:Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
         type:PostalAddress
      name:University of Oxford
      address:
         name:Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Markus Reindl
      url:http://orcid.org/0000-0003-2817-1402
      affiliation:
            name:Medical University of Innsbruck
            address:
               name:Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Patrick Waters
      affiliation:
            name:University of Oxford
            address:
               name:Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
      name:Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(401)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Foundation
  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.86s.